Article

Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion

HIV Epidemiology & Biostatistics Group, Research Department of Infection and Population Health, Royal Free Campus, UCL (Royal Free Campus), London, UK.
AIDS (London, England) (Impact Factor: 6.56). 06/2010; 24(10):1561-7. DOI: 10.1097/QAD.0b013e32833a6056
Source: PubMed

ABSTRACT Understanding of the interplay between plasma HIV RNA level and CD4 cell count depletion in untreated infection remains incomplete.
We studied 1169 people with HIV seen for care at a major London clinic while naive to antiretroviral therapy. We considered pairs (n = 5940) of consecutive simultaneously measured CD4 cell count and plasma HIV RNA values from patients who had never started therapy. Baseline was the first date when both measures were known.
HIV RNA levels increased variably and often substantially from baseline (60% experience an increase of over 50 000 copies/ml by 5 years of follow-up). The current HIV RNA level (i.e. first value of the pair) was strongly associated with the time-standardized change in CD4 cell count, with a mean 106 cells/microl per year greater rate of CD4 cell count decline per log-copy/ml higher current HIV RNA level (P < 0.0001). After adjustment for the current level, higher baseline HIV RNA was not associated with CD4 cell count decline. There was no average CD4 cell count decline with current HIV RNA level below 3.0 log-copies/ml, compared with a 159 cells/microl per year decline for those with HIV RNA at least 5.5 log-copies/ml (P < 0.0001). Further, the current CD4 cell count predicted subsequent changes in HIV RNA level (0.04 log-copies/year greater increases per 100 cells/microl lower CD4 cell count; P < 0.0001).
The often substantial increases in HIV RNA level observed in untreated HIV infection appear fundamentally linked to CD4 cell count depletion. Research into mechanisms by which HIV RNA levels rise over time should yield insights into the causes of CD4 cell count depletion, as the two processes are intimately linked.

Full-text

Available from: Valentina Cambiano, Jun 13, 2015
0 Followers
 · 
210 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Among antiretroviral therapy (ART)-naive individuals, viral load levels tend to increase and CD4þ cell counts decline over time. We sought to explore the rate of change and influence of other factors associated with these markers of HIV progression. Design: An observational cohort collaboration study. Methods: A total of 158 385 pairs of consecutive viral load and CD4þ cell count simultaneously measured from 34 384 ART-naive individuals in the COHERE database were analysed. Annual changes and factors associated with these changes were estimated using generalized estimating equations. Results: Viral load continued to rise at a mean [95% confidence interval (CI)] rate of 0.091 (0.086–0.096) log10 copies/ml per year. A faster rise in viral load was significantly associated with older age, such that for every 10 years older, it was a mean 0.022 log10 copies/ml per year greater. The mean (95% CI) CD4þ cell count change was �78.0 (�80.1 to �76.0) cell/ml per year and it was strongly associated with a higher current viral load: for every 1 log10 copies/ml higher, CD4þ cell count declined by an additional 37.6 cells/ml per year (P<0.001). Current viral load was a stronger predictor of CD4þ cell count depletion than baseline viral load. Neither sex, race nor transmission by injecting drug use was associated with change in either the viral load or CD4þ cell count. Discussion: We found that in ART-naive individuals, viral load continues to increase over time and more sharply in those who are older. Our results also suggest that higher current viral load is strongly associated with ongoing rate of CD4þ cell count depletion.
    AIDS 06/2014; 28:1351-1356. DOI:10.1097/QAD.0000000000000224 · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE OF REVIEW: The declaration of the United Nations High Level meeting on AIDS in June 2011 includes 10 concrete targets, including to ensure that there are 15 million people living with human immunodeficiency virus (HIV) on antiretroviral treatment (ART) by 2015. This review examines the potential, opportunities and challenges of treatment as prevention of HIV and tuberculosis (TB) in reaching this target. RECENT FINDINGS: Although around 8 million people are on treatment, everyone living with HIV will eventually need ART to stay alive. As many as 24 million people living with HIV today are not on treatment, the majority not even being aware of their HIV infection. Expansion of a comprehensive prevention strategy including providing ART to 15 million or more people would significantly reduce HIV and TB morbidity, mortality and transmission. The challenges include ensuring human rights protections, steady drug supply, early diagnosis and linkage to care, task shifting, adherence, retention, and monitoring and evaluation. Expansion could also lead to the control and possible elimination of HIV in many places. SUMMARY: Achieving an 'AIDS-free generation' whereby deaths related to HIV are drastically reduced, people living with HIV are AIDS-free on ART, and HIV transmission is decreased, is both scientifically sound and practically feasible. The global community could reach 15 million people on ART by 2015 while expanding our vision and efforts to include diagnosis and treatment for all the 32 million people living with HIV in the future.
    Current opinion in HIV and AIDS 11/2012; DOI:10.1097/COH.0b013e32835b80dd · 4.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE:: The current CDC guidelines from 2006 recommend a one-time test for low risk individuals and annual testing for those at high risk. These guidelines may not be aggressive enough, even for those at low risk of infection, due to the earlier initiation of highly active antiretroviral therapy (HAART) and a movement toward a test-and-treat environment. We evaluate the optimal testing frequencies for various risk groups in comparison to the CDC recommendations. METHODS:: We build a deterministic mathematical model optimizing the tradeoff between the societal cost of testing and the benefits over a patient's lifetime of earlier diagnosis. RESULTS:: Under a test-and-treat scenario with immediate initiation of HAART, the optimal testing frequency is every 2.4 years for low risk (0.01% annual incidence) individuals; every nine months for moderate risk (0.1% incidence) individuals; and every three months for high risk (1.0% incidence) individuals. The incremental cost-effectiveness of the optimal policy is $36 342/QALY for low risk individuals and $45 074/QALY for high risk individuals, compared to 10-year and annual testing respectively. CONCLUSIONS:: The current CDC guidelines for HIV testing are too conservative and more frequent testing is cost-effective for all risk groups.
    AIDS (London, England) 11/2012; DOI:10.1097/QAD.0b013e32835c54f9 · 6.56 Impact Factor